Stock comparison
Merck & Co., Inc. is 214.9x more valuable than KalVista Pharmaceuticals, Inc. by market capitalization ($308.90 B vs $1.44 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
MRK is larger
Merck & Co., Inc. is 214.9x more valuable than KalVista Pharmaceuticals, Inc. by market capitalization ($308.90 B vs $1.44 B).
Market value leader
MRK
Merck & Co., Inc. is 214.9x more valuable than KalVista Pharmaceuticals, Inc. by market capitalization ($308.90 B vs $1.44 B).
Revenue leader
MRK
KALV: $50.00M vs MRK: $65.01B.
Profit leader
MRK
KALV: -$183.40M vs MRK: $18.25B.
Margin leader
MRK
KALV: -366.8% vs MRK: 28.1% net margin.
| Metric | KALV | MRK |
|---|---|---|
| Market cap | $1.44 B | $308.90 B |
| US-listed rank | #2383 | #45 |
| Revenue (latest FY) | $50.00M | $65.01B |
| Net income (latest FY) | -$183.40M | $18.25B |
| Net margin | -366.8% | 28.1% |
| P/E (trailing FY) | - | 16.9x |
| SEC filings | 834 | 998 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
Merck & Co., Inc. is 214.9x more valuable than KalVista Pharmaceuticals, Inc. by market capitalization ($308.90 B vs $1.44 B).
Full pages: KalVista Pharmaceuticals, Inc. and Merck & Co., Inc., or browse the full rankings.